Triptolide decreases expression of latency-associated nuclear antigen 1 and reduces viral titers in Kaposi's sarcoma-associated and herpesvirus-related primary effusion lymphoma cells

International Journal of Oncology
Cong LongXiaoping Sun

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) can establish a life-long persistence in the host after primary infection and is associated with certain malignancies, which are resistant to conventional chemotherapeutic agents with a poor prognosis. Latency-associated nuclear antigen 1 (LANA1) encoded by KSHV is essential for segregation, replication and maintenance of viral genome. In addition, LANA1 upregulates the transcriptional activity of signal transducer and activator of transcription 3 (STAT3), which plays an important role in promoting survival of KSHV-associated primary effusion lymphoma (PEL) cells. Furthermore, LANA1 mediates transcriptional modulation of KSHV and host genome in host cells. In the present study, the antitumor effect of triptolide was assessed. CCK-8 assays were performed to demonstrate that the proliferations of PEL cells were efficiently inhibited by triptolide in a dose- and time-dependent manner. Flow cytometric results indicated that triptolide induced cell cycle arrest and apoptosis. Western blot results suggested that triptolide downregulated LANA1 expression and reduced half-life of LANA1 in the KSHV-infected malignant cells. Viral titer experiments indicated that triptolide treatment impaire...Continue Reading

References

Oct 4, 1972·Journal of the American Chemical Society·S M KupchanR F Bryan
Feb 13, 2001·Annual Review of Medicine·C Boshoff, Y Chang
Jul 24, 2004·Blood·Annika JärviluomaPäivi M Ojala
Sep 28, 2004·The Journal of General Virology·Veronika P PozharskayaMargaret K Offermann
Jul 5, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Emmanuelle BoulangerEric Oksenhendler
Nov 28, 2006·Frontiers in Bioscience : a Journal and Virtual Library·John Nicholas
Oct 3, 2007·Cancer Research·Phoebe A PhillipsAshok K Saluja
Feb 6, 2010·Proceedings of the National Academy of Sciences of the United States of America·Xiaoping SunShannon C Kenney
Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Kristopher A SarosiekIzidore S Lossos
Jan 25, 2011·International Immunopharmacology·Qiuyan Liu
Jul 5, 2011·Journal of Molecular Biology·Gregory M LeeCharles S Craik
Jun 13, 2012·Biological & Pharmaceutical Bulletin·Chizuka HigashiMasahiro Fujimuro
Oct 19, 2012·Science Translational Medicine·Rohit ChughAshok K Saluja
Jul 25, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ramakrishnan GopalakrishnanPreet M Chaudhary
Oct 17, 2013·The Journal of Biological Chemistry·Sulagna BanerjeeAshok K Saluja
Jul 30, 2014·Proceedings of the National Academy of Sciences of the United States of America·Qiming SunKenneth Kaye
Nov 26, 2014·Viruses·Natacha CoenGraciela Andrei
Dec 17, 2014·Biochemical and Biophysical Research Communications·Heng ZhouXiaoping Sun
Dec 17, 2014·Viruses·Timsy UppalErle S Robertson

❮ Previous
Next ❯

Citations

Apr 12, 2017·Current Opinion in Pulmonary Medicine·Nivedita AroraNavid Sadeghi
Dec 10, 2020·Medicinal Research Reviews·Yanqiong ZhangNa Lin
Jul 3, 2021·Investigational New Drugs·Ean-Jeong SeoThomas Efferth
May 2, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Yaqian ZhangXiaoping Sun

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis